Lineage And William Demant Collaborate Through Investment To Develop ReSonance For Hearing Loss
Benzinga Newsdesk 1 year ago
News
Three-year term intended to advance preclinical development of ReSonanceUp to $12 million of development costs to be contributed by William Demant Invest
- Three-year term intended to advance preclinical development of ReSonance
- Up to $12 million of development costs to be contributed by William Demant Invest